Skip to content
Log in
Sponsored Artificial Intelligence: A Modern Approach, Global Edition Artificial Intelligence: A Modern Approach, Global Edition
Open access

Plasma p‐tau217 detects Alzheimer's disease co‐pathology in cerebral amyloid angiopathy: Comparison to CSF biomarkers in the ANGMAR cohort

A. Fernández-Lebrero J. Jiménez-Balado G. García-Escobar José Contador Isabel Estragués‐Gázquez Laia Peraferrer-Montesinos Rosa-María Manero-Borràs L. Gramegna M. Viles A. R. Campello P. Ortiz-Romero M. De Diego M. del Campo J. Torres‐Torronteras E. Jiménez‐Moyano H. Blasco‐Forniés M. Suárez-Calvet Á. Ois Albert Puig-Pijoan I. Navalpotro-Gómez
Aug 2026 · Alzheimer's & Dementia · Vol 22 · 0 citations · 27 references
Medicine

TL;DR

Plasma phosphorylated tau (p‐tau)217 is a robust biomarker of AD, but its performance in CAA remains unclear.

Abstract

Cerebral amyloid angiopathy (CAA) frequently co‐occurs with Alzheimer's disease (AD), generating mixed vascular–neurodegenerative phenotypes. Plasma phosphorylated tau (p‐tau)217 is a robust biomarker of AD, but its performance in CAA remains unclear.

DOI PubMed Semantic Scholar
Read PDF

Similar papers

Open access Sep 2026

Changes in serum β‐synuclein precede blood biomarkers of Alzheimer pathology in Down syndrome

There is a need for early, objective markers of Alzheimer's disease (AD)‐related synapse dysfunction in adults with Down syndrome (DS). The presynaptic protein β‐synuclein is elevated in the blood of adults with DS. This study evaluates the positioning of these changes relative to changes in pathophysiological blood bi...

Alba Cervantes González, A. Morcillo-Nieto, Sara Serrano et al. · 0 citations
Review Open access Sep 2026

CSF Tau and Amyloid Biomarkers in Cognitive Impairment Across the ALS–FTD Spectrum: A Systematic Narrative Review and Evidence Map

Cognitive impairment is an important non‐motor manifestation of amyotrophic lateral sclerosis (ALS), particularly across the ALS–frontotemporal dementia (ALS–FTD) spectrum. Cerebrospinal fluid (CSF) tau and amyloid biomarkers may reflect nonspecific neurodegenerative injury, concomitant Alzheimer disease (AD) pathology...

Aasim Ali, Muhammad Arif, Usama Ashraf et al. · 0 citations
Open access Sep 2026

TMEM106B is a selective modulator of TDP‐43 pathology in Alzheimer's disease

Co‐pathologies – including Lewy body, vascular, and TDP‐43 lesions – are common in Alzheimer's disease (AD), contributing to its clinical and pathological heterogeneity. Genetic risk factors may drive mixed pathology presentation, but their influence on the development of specific co‐pathologies remains unclear.

Madison M. Reeves, Anna Calliari, Tiffany W. Todd et al. · 0 citations
Open access Sep 2026

Cerebrospinal Fluid p75 Neurotrophin Receptor Ectodomain Levels Across Clinically Diagnosed Alzheimer's Disease, Late‐Life Depression, and Healthy Aging: A Preliminary Cross‐Sectional Study

The p75 neurotrophin receptor ectodomain (p75NTR‐ECD) has been implicated in amyloid‐β‐related neurotoxicity, but cerebrospinal fluid (CSF) levels in late‐life depression (LLD) remain uncertain. We compared clinically diagnosed Alzheimer's disease (AD), LLD, and healthy controls (HC) and reassessed exploratory symptom...

W. Omori, N. Kajitani, M. Okada-Tsuchioka et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.